Диссертация (1139946), страница 27
Текст из файла (страница 27)
10–YearFollow–up of Intensive Glucose Control in Type 2 Diabetes. N. Engl. J. Med.2008. - №359. – Р.1577–89123.Holzmann S. et al. / Eur. J. Pharmacol. -1992. - V. 215. - № 1. - Р. 1.124.Horinaka S. et al.; JCAD Study Investigators / Circ. J. - 2010. - V. 74. -№3. - Р.504.125.Horinaka S. /Drugs. - 2011. - V. 71. - № 9. - P. 1105.126.Horinaka S., Yabe A., Yagi H., Ishimitsu T., Yamazaki T., Suzuki S.,KohroT.,NagaiCARDIORENALR.DEPARTMENTMEDICINE,OFDOKKYOHYPERTENSIONMEDICALANDUNIVERSITY,TOCHIGI. Russian Journal of Cardiology.- 2011. -№2.- Р.111-119.127.Inagami T., Naruse M., Hoover R. Endothelium as an endocrine organ/Annu. Rev.
Physiol. – 1995.-Vol. 57.-P.171-189.128.Ishihara S. et al. / Circ. J. - 2012. - V. 76. - № 5. - P. 1169.129.Ishibashi Y. et al. Effects of long-term nicorandil administration onendothelial function. inflammation, and oxidative stress in patients withoutcoronary artery disease / J. Cardiovasc. Pharmacol. — 2008. — Vol. 51. —№ 3.— P. 311.130.Iwakura K., Ito H., Okamura A., Koyama Y. et al. Nicorandil treatmentin patients with acute myocardial infarction: Ameta-analisis/ Circ J. – 2009. –Vol.73 -P. 925-931.131.Izumiya Y., Kojima S., Kojima S.
et al. Longterm use of oralnicorandil stabilizes coronary plaque in patients with stable angina pectoris /Atherosclerosis. — 2011. — P. 415–421.132.Jiang J., Li Y., Zhou Y., et al. Oral nicorandil reduces ischemic attacks inpatients with stable angina: A prospective, multicenter, open-label, randomized,controlled study / Int J Cardiol. – 2016. -№224. – Р.183-7.133.Kambara H, Yamazaki T, Hayashi D et al. Gender differences in patientswith coronary artery disease in Japan: The Japanese Coronary Artery DiseaseStudy (the JCAD study) / Circ J. – 2009. - №73. – Р.912-917.170134.Karasu, C.
Glycoxidative stress and cardiovascular complications inexperimentally-induced diabetes: effects of antioxidant treatment / OpenCardiovasc. Med. J. – 2010. –Vol. 4. – P. 240–256135.Kasama S, Toyama T, Iwasaki T, et al. Effects of oral nicorandil therapyon sympathetic nerve activity and cardiac events in patients with chronic heartfailure: subanalysis of our previous report using propensity score matching /Eur JNucl Med Mol Imaging . – 2014.
-№41. – Р.144–154136.Kinoshita M., Sakai K. Pharmacology and Therapeutic Effects ofNicorandil. Cardiovasc/ Drugs and Therapy.- 1990.- №4. – Р. 1075–1088.137.Kitakaze M., Asakura M., Kim J. et al. Human atrial natriuretic peptideand nicorandil as adjuncts to reperfusion treatment for acute myocardialinfarction (J-WIND): two randomised trials. Lancet.
- 2007. -№ 370. – Р.1483–93.138.Kones R . R ecent advances in the management of chronic stable anginaII. Anti-ischemic therapy, options for refractory angina, risk factor reduction, andrevascularization/ Vasc Health Risk Manag. – 2010. - № 6. – Р.749-74.Kukovetz W.R. et al. / J. Cardiovasc. Pharmacol. - 1991. - V. 17. - № 4.139.- P.627140.Kusama Y., Kodani E., Nakagomi A., Otsuka T., Atarashi H., Kishida H.,Mizuno K. Variant angina and coronary artery spasm: the clinical spectrum,pathophysiology, and management /J. Nippon. Med. Sch. — 2011.
—Vol. 78. —№ 1. — P. 4–12.141.Lee Н. С., An S. G., Choi J. H. et al. Effect of intra-coronary nicorandiladministration prior to ≪perfusion in acute ST segment elevation myocardialinfarction / Circ. J. 2008. — Vol. 72. — P. 1425–1429.142.Lee HL, Chang PC, Chou CC, et al. Blunted proarrhythmic effect ofnicorandil in a Langendorff-perfused phase-2 myocardial infarction rabbitmodel/ Pacing Clin Electrophysiol.
- 2013. - №36. –Р.142–151.143.Lee T.M., Chou T.F. Impairment of myocardial protection in type 2diabetic patients / J.Clin Endocrinol Metab. – 2003. – Vol. 88. – Р.531-537.171144.Lusher T.F. Endothelium in the control of vascular tone and growth roleof local mediators and mechanical forces/Blood Press. Suppl.- 1994.-№ 1. – Р.18-22.145.Mancini GBJ, Henry GC, Macayac et al.
Angiotensin-converting enzymeinhibition with quinapril improves endothelial vasomotor dysfunction in patientswith coronary artery disease. The TREND (Trial on Reversing EndothelialDysfunction) study/ Circulation. - 1996.- № 94. –Р. 258-65146.Meany T.B., Richardson P., Camm A.J., Coltart J., Griffith M., MaltzM.B., Signy M. Exercise capacity after single and twice-daily doses of nicorandilin chronic stable angina pectoris/ Amer. J. Cardiology. - 1989. -№ 63. –Р.66–70.147.Michael T., Gewaltig M., Kojda G.
Vasoprotection by nitric oxide:mechanisms and therapeutic potential / Cardiovascular research. -2002.-V.55.P.205-260.148.McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for thediagnosis and treatment of acute and chronic heart failure 2012: the task force forthe diagnosis and treatment of acute and chronic heart failure 2012 of theEuropean society of cardiology Developed in collaborationwith the Heart FailureAssociation (HFA) of the ESC/ Eur Heart J. - 2012. - №33.
–Р.1787–1847149.Momboli J.V., Vanhoutte P.M. Endothelial function after converting-enzyme inhibition //Medicographia. — 1996. — Vol. 18, № 1. — P. 35-40.150.Montalescot G., Sechtem U., Achenbach S. on behalf of authors 2013ESC guidelines on the management of stable coronary artery disease: The TaskForce of the European Society of Cardiology/ Eur Heart J. - 2013. - №34(38). –Р.2949—3003.151.Nakamura M., Yoshida H., Arakawa N., Mizunuma Y., Makita S.,Hiramori K.
Endothelium-dependent vasodilatation is not selectively impaired inpatients with chronic heart failure secondary to valvular heart disease andcongenital heart disease/ E. Heart J. – 1996. - №17. – Р.1875-1882.172152.Nissen S.E., Tuzcu E.M., Libby P. et al., for the CAMELOTInvestigators. Effect of antihypertensive agents on cardiovascular events inpatients with coronary disease and normal blood pressure: the CAMELOT study:randomized controlled trial /JAMA.
- 2004. - № 292.- Р. 2217–25.153.Okura T, Higaki J, Kurata M et al. Elevated serum uric acid is anindependent predictor for cardiovascular events in patients with severe coronaryartery stenosis: Subanalysis of the Japanese Coronary Artery Disease (JCAD)Study / Circ J. - 2009.
-№ 73. – Р. 885 – 891.154.The Heart Outcomes Prevention Evaluation Study Investigators. Effectsof an angiotensin–converting–enzyme inhibitor, ramipril, on death fromcardiovascular causes,myocardial infarction and stroke in high–risk patients/New Engl J Med. – 2000 . -№ 342. – Р.145–153.155.The IONA Study Grup.Effect of nicorandil on coronary events in patientswith stable angina: the Impact Of Nicorandil in Angina (IONA): randomized trial/ Lancet. - 2002 .
- №359. – Р.1269–75.156.The Task Force on the management of stable coronary artery disease ofthe European Society of Cardiology. 2013 ESC guidelines on the management ofstadle coronary artery disease/ Our Heart J. - 2013. - № 34(38). – Р. 2949-3003157.Rezkalla S.H., Kloner R.A.
Preconditioning in humans. Heart Fail Rev2007; 12: 201-206.Panza J., Quyyumi A., Brush J. Abnormal endothelium-dependent vascular relaxation in patientswith essential hypertension./N.Engl.J.Med. – 1990. -№ 3223. – Р.22-27.158.Roland E. Safety profile of an anti-anginal agent with potassium channelopening activity: an overview. Europ. Heart J., 1993.- 14(Suppl. B): 40–47.159.Role of Adenosine and Nitric Oxide on the Mechanisms of Action ofDipiridamole/ Stroke.-2005.-V.36.- P.2170-2175.160.Sakata Y., Nakatani D., Shimizu M. et al. Oral treatment with nicorandilat discharge is associated with reduced mortality after acute myocardialinfarction/ J.
Cardiol. — 2012. — V. 59. — № 1. — P. 14–21.173161.Secco GG, Parisi R, Mirabella F, et al. Old and New Drugs for TreatmentofStableAngina:Anti-AnginalDrugsandCoronaryRevascularization/Cardiovasc Hematol Agents MedChem. – 2015. - № 13 (1). –Р. 21-4.162.Schiller N.B. Considerations in the standartization of measurement ofleft ventricular myocardial mass by two-dimensional echocardiography./Hypertension. - 1987. -V. 9. - P. 11-13.163.Schunkert H, Erdmann J, Samani NJ.
Genetics of myocardial infarction:a progress report./Eur Heart J. - 2010. -№ 31 (8). – Р.918–925164.N4) Shimbo D., Grahame-Clarke C., Miyake Y., Rodriguez C., SciaccaR., Di Tullio M., Boden-Albala B., Sacco R., Homma S. The associationbetween endothelial dysfunction and cardiovascular outcomes in a populationbased multi-ethnic cohort/ Atherosclerosis. – 2007. -№192(1). – Р.197-203.165.Sinoway L., Hendrickson C., Davidson W. et al. Characteristics of flow-mediated brachial artery vasodilatation in human subjects/ Circul. Res. - 1989.№64.
– Р. 32-42.166.Strojek K., Yoon K.H., Hruba V. et al. Effect of dapagliflozin in patientswith type 2 diabetes who have in adequate glycaemic control with glimepiride: arandomized, 24-week, double-blind, placebo-controlled trial / Diabetes, Obesityand Metabolism. – 2011. – Vol. 13. – Р. 10.167.Taira N. Nicorandil as a Hybrid Between Nitrates and Potassium ChannelActivators/Amer. J.
Cardiology. - 1989 - №63(21). – Р.12-23.168.Vanhoutte P.M. Endothelial dysfunction and aterosclerosis / Eur. HeartJ.-1997.- №18 (Suppl. E).- P. 19-29.169.Vogel R. Coronary risk factors, endothelial function and atherosclerosis:a review/ Clin. Cardioloogy. - 1997. - v.20. – Р.426-432.170.Wilson S. R., Scirica B. M., Braunwald E. еt al. Efficacy of ranolazine inpatients with chronic angina obser vations from the randomized, double-blind,placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazinefor174Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36Trial /J. Am.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
